enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.22 ^USD	+0.77%		-5.09%	+1.56%

Apr. 16	EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	CI
Apr. 09	EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	CI

EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023

February 29, 2024 at 04:30 pm EST

enVVeno Medical Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 23.52 million compared to USD 24.67 million a year ago. Basic loss per share from continuing operations was USD 1.91.

Diluted loss per share from continuing operations was USD 1.91.

Latest news about enVVeno Medical Corporation

EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	Apr. 16	CI
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer	Apr. 09	CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	Mar. 06	MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	Mar. 06	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	Nov. 16	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
EnVVeno Achieves Full Enrollment for VenoValve Trial; to Conduct Preclinical Trial of Another Venous Valve Product	23-10-06	MT
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial	23-10-06	CI
EnVVeno Medical Corporation announced that it expects to receive $27.997135 million in funding	23-10-05	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study	23-07-05	CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell 3000E Growth Index	23-06-23	CI
EnVVeno Medical Corporation(NasdaqCM:NVNO) added to Russell Microcap Growth Index	23-06-23	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Envveno Medical Promotes Hamed Alavi to Senior Vice President and Chief Technology Officer	23-01-18	CI
Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria	22-11-17	CI
EnVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study	22-11-07	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-03	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
EnVVeno Medical Secures US Patent for Manufacturing Method Related to VenoValve	22-04-11	MT
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI

Chart enVVeno Medical Corporation

Duration

Period

More charts

Company Profile

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

Sector

Biotechnology & Medical Research

Calendar

2024-11-06 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.18 USD

Average target price

20.4 USD

Spread / Average Target

+293.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENVVENO MEDICAL CORPORATION	+1.56%	68.98M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research